This phase II trial is evaluating an investigational drug (entrectinib) for the treatment of patients with solid cancers that express the NTRK1/2/3, ROS1 or ALK gene.
This trial is treating multiple types of cancer including Breast, Colorectal, Lymphoma, Melanoma, Neuroendocrine, Non Small Cell Lung Cancer, Ovarian, Pancreatic, Thyroid, Brain, Renal Cell, Kidney, Sarcoma, Salivary Gland.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Commercial Sponsor
Ignyta, Inc.
Summary
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene rearrangement. Patients will be assigned to different baskets according to tumor type and gene rearrangement. NSCLC and mCRC will be the main patient populations of interest.
*Note: Patients diagnosed with anaplastic large cell lymphoma (ALCL) harboring a gene rearrangement of interest may be eligible provided they meet all other inclusion/exclusion criteria*
Not Recruiting Hospitals Read More